TET2 and myeloid leukemia: In mouse model studies, Asxl1 along with Tet methylcytosine dioxygenase 2 (Tet2) mutation initiated MDS-like hematopoietic impairment [92,96], and concurrent oncogenic mutations such as Kras and Nf1 accelerated the development of myeloid leukemia [97].